Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Edwards Lifesciences sent a formal request to CMS in February after its Evoque TTVR device gained FDA approval. The agency is now accepting public comments for 30 days.
Hydra TAVR valve gains key approval as global reach continues to grow
The self-expanding device is now available in more than 20 countries and received CE mark approval back in 2020. However, it has not yet been approved by the U.S. Food and Drug Administration for use in the United States.
SAVR outperforms TAVR in patients with bicuspid aortic valves
BAV patients are often excluded from TAVR trials, creating uncertainty about the best way to treat that population when aortic valve replacement is required. To learn more, researchers tracked CMS data from 2018 to 2022, presenting their findings in The Annals of Thoracic Surgery.
Intravascular lithotripsy technology now a top priority for many healthcare companies
After the significant success of Shockwave Medical's IVL therapy to break up heavily calcified vessels without trauma, there are now several companies working on their own IVL devices.
SCAI president reviews achievements in interventional cardiology in 2024
SCAI President James Hermiller, MD, recently outlined the key achievements for 2024, including creation of the first interventional cardiology match program, successful advocacy and efforts to increase women in the field.

Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.

'Promising' new data on TMVr among cancer patients

The study's authors examined data from nearly 23,000 patients who underwent transcatheter mitral valve repair from 2014 to 2018.

June 13, 2022

Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health, a collaboration between Ascension Texas and the University of Texas at Austin, including its Dell Medical School. This new, state-of-the-art cardiology program fully integrates all the cardiac subspecialties to create a comprehensive heart team approach in treating patients.

VIDEO: Creating an integrated heart team program in central Texas

Charles D. Fraser, Jr., MD, executive director of the new Institute for Cardiovascular Health in Austin, Texas, discusses the facility's new, state-of-the-art cardiology program.

June 8, 2022

Links to all the SCAI 2022 late-breaking clinical research

The Society for Cardiovascular Angiography and Interventions (SCAI) has announced its late-breaking study presentations at its 2022 Scientific Sessions.

June 8, 2022

The Advanta V12 and iCast (bottom image) balloon expandable covered stents were recalled by Atrium/Getinge because the balloons may not deflate quickly when using thicker contrast for endovascular use.

More than 68,000 stents recalled after multiple injuries

Dozens of customers have reported issues with the device’s balloon or catheter hub separating from the delivery system, mostly during off-label use in a patient's blood vessels.

June 2, 2022

Abbott’s FreeStyle Libre 3 glucose monitor gains FDA clearance

Regulatory Roundup: FDA clears 2 new devices, grants breakthrough designation to advanced AI model

Catch up on several recent FDA announcements, including an update on the agency's response to the COVID-19 pandemic.

June 1, 2022

Survival on the rise among high-risk pulmonary embolism patients

The study's authors examined data from more than 1.4 million patients, noting that pulmonary embolism response teams appear to be playing a significant role.

May 31, 2022